Callan Family Office LLC Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Callan Family Office LLC acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,911 shares of the medical equipment provider's stock, valued at approximately $1,153,000.

A number of other large investors also recently modified their holdings of ZBH. Roman Butler Fullerton & Co. purchased a new stake in Zimmer Biomet in the 4th quarter valued at $473,000. Geode Capital Management LLC raised its stake in shares of Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock valued at $524,942,000 after buying an additional 125,852 shares during the period. M&T Bank Corp lifted its position in shares of Zimmer Biomet by 48.4% during the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock valued at $2,884,000 after buying an additional 8,709 shares during the last quarter. KLCM Advisors Inc. purchased a new position in shares of Zimmer Biomet in the fourth quarter worth about $7,825,000. Finally, Peddock Capital Advisors LLC bought a new stake in Zimmer Biomet during the 4th quarter valued at $654,000. 88.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.95% of the stock is currently owned by company insiders.

Remove Ads

Wall Street Analyst Weigh In

ZBH has been the subject of several research analyst reports. Barclays dropped their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. JMP Securities reissued a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, Zimmer Biomet has a consensus rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Stock Down 3.0 %

ZBH stock traded down $3.24 during midday trading on Wednesday, reaching $104.10. 1,916,534 shares of the company were exchanged, compared to its average volume of 1,903,109. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a market cap of $20.72 billion, a price-to-earnings ratio of 23.39, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The stock's 50-day simple moving average is $105.68 and its 200 day simple moving average is $107.08. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the firm earned $2.20 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. Zimmer Biomet's dividend payout ratio (DPR) is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.